4.7 Article

Epigenome editing of microsatellite repeats defines tumor-specific enhancer functions and dependencies

Journal

GENES & DEVELOPMENT
Volume 32, Issue 15-16, Pages 1008-1019

Publisher

COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/gad.315192.118

Keywords

Ewing sarcoma; pediatric cancer; epigenetics; EWS-FLI1; enhancer therapy; epigenome editing

Funding

  1. Medic Foundation
  2. Swiss Cancer Research Foundation
  3. Botnar Foundation
  4. Swiss National Science Foundation [310030_169563, PP00P3-157468/1]
  5. Swiss Cancer League [KLS 3365-02-2014]
  6. Oncosuisse [KFS-3973-08-2016]
  7. V Foundation for Cancer Research
  8. Charley Davidson Children's Cancer Fund at the MassGeneral Hospital for Children
  9. Swiss National Science Foundation (SNF) [310030_169563, PP00P3_157468] Funding Source: Swiss National Science Foundation (SNF)

Ask authors/readers for more resources

Various types of repetitive sequences are dysregulated in cancer. In Ewing sarcoma, the oncogenic fusion protein EWS-FLI1 induces chromatin features typical of active enhancers at GGAA microsatellite repeats, but the function of these sites has not been directly demonstrated. Here, by combining nascent transcription profiling with epigenome editing, we found that a subset of GGAA microsatellite repeats is transcriptionally active in Ewing sarcoma and that silencing individual repeats abolishes local nascent transcription and leads to markedly reduced expression of putative target genes. Epigenome silencing of these repeat sites does not affect gene expression in unrelated cells, can prevent the induction of gene expression by EWS-FLI1, and, in the case of a GGAA repeat that controls SOX2 expression from a distance of 470 kb, is sufficient to impair the growth of Ewing sarcoma xenografts. Using an experimental approach that is broadly applicable to testing different types of repetitive genomic elements, our study directly demonstrates that specific repeat microsatellites can have critical gene regulation functions in cancer and thus represent tumor-specific vulnerabilities that may be exploited to develop new therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available